Skip to content

Renal Osteodystrophy: A Fresh Approach

Renal Osteodystrophy: A Fresh Approach

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00859612
Enrollment
464
Registered
2009-03-11
Start date
2009-03-31
Completion date
2014-02-28
Last updated
2017-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Osteodystrophy

Brief summary

There are two major goals of this project: 1. Comparison of DXA and QCT for diagnosis of bone loss in CKD-5 patients and determination of the prevalence of low bone turnover in CKD-5 patients with bone loss. 2. Identification of the optimal combination of noninvasive tests for definition of the turnover component of ROD.

Interventions

None listed

Sponsors

Hartmut Malluche, MD
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Aged 18 years or older; * Chronic maintenance dialysis of at least 3 months' duration; * Mental competence; * Willingness to participate in the study; * Calcidiol levels within normal range.

Exclusion criteria

* Pregnancy; * Systemic illnesses or organ diseases that may affect bone (except type 1 or type 2 diabetes mellitus); * Clinical condition that may limit study participation (e.g., unstable angina, respiratory distress, infections). * Chronic alcoholism and/or drug addiction; * Participation in a study of an investigational drug during the past 90 days; * Allergy to tetracycline. * Planning to move out of the area within 2 years of the study; * On active transplant list; * Treatment within last 6 months with drugs that may affect bone metabolism (except for treatment with calcitriol, vitamin D analogs and/or calcimimetics). * Calcidiol level below the normal range. The current routine clinical practice in our dialysis clinics is to check calcidiol status twice yearly and supplement with vitamin D according to serum calcidiol levels. It is therefore unlikely that a substantial number of patients will be excluded due to this exclusion criterion.

Design outcomes

Primary

MeasureTime frameDescription
Comparison of DXA and QCT for diagnosis of bone loss in CKD-5 patients and determination of the prevalence of low bone turnover in CKD-5 patients with bone loss.4 yearsBecause each method (QCT or DXA) yields a dichotomous response (bone loss: yes or no), the proportion of patients with a bone loss will be compared between the 2 methods by using the McNemar statistic for correlated proportions.

Secondary

MeasureTime frameDescription
Identification of the optimal combination of noninvasive tests for definition of the turnover component of ROD.4 yearsA stepwise logistic model will be used to determine which combination of PTH and bone markers best predicts low bone turnover.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026